Dynavax Technologies Corporation (NASDAQ:DVAX) shares traded down 9.4% on Tuesday . The stock traded as low as $18.20 and last traded at $18.35. 4,069,700 shares were traded during mid-day trading, an increase of 115% from the average session volume of 1,889,366 shares. The stock had previously closed at $20.25.
Several research analysts have recently weighed in on the company. Cowen and Company restated a “buy” rating and issued a $30.00 price target on shares of Dynavax Technologies Corporation in a research note on Friday, November 3rd. Cantor Fitzgerald assumed coverage on Dynavax Technologies Corporation in a research report on Friday, September 15th. They set an “overweight” rating and a $24.00 price objective for the company. Royal Bank Of Canada reiterated an “outperform” rating and set a $28.00 price objective (up previously from $26.00) on shares of Dynavax Technologies Corporation in a research report on Monday, September 25th. ValuEngine raised Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a report on Thursday, September 7th. Finally, William Blair reissued an “outperform” rating and set a $30.00 price target on shares of Dynavax Technologies Corporation in a report on Wednesday, August 9th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Dynavax Technologies Corporation presently has an average rating of “Buy” and a consensus price target of $25.17.
Dynavax Technologies Corporation (NASDAQ:DVAX) last announced its quarterly earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.15. Dynavax Technologies Corporation had a negative return on equity of 65.97% and a negative net margin of 1,177.60%. The company had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.28 million. During the same period in the prior year, the company earned ($0.90) earnings per share. The firm’s revenue was down 68.8% on a year-over-year basis. analysts expect that Dynavax Technologies Corporation will post -1.72 EPS for the current fiscal year.
Hedge funds have recently modified their holdings of the business. Swiss National Bank raised its position in Dynavax Technologies Corporation by 25.5% during the second quarter. Swiss National Bank now owns 70,978 shares of the biopharmaceutical company’s stock valued at $685,000 after purchasing an additional 14,400 shares during the period. Russell Investments Group Ltd. raised its holdings in shares of Dynavax Technologies Corporation by 24.0% in the second quarter. Russell Investments Group Ltd. now owns 155,095 shares of the biopharmaceutical company’s stock worth $1,496,000 after buying an additional 30,036 shares during the period. Patriot Financial Group Insurance Agency LLC raised its holdings in shares of Dynavax Technologies Corporation by 50.0% in the third quarter. Patriot Financial Group Insurance Agency LLC now owns 18,000 shares of the biopharmaceutical company’s stock worth $419,000 after buying an additional 6,000 shares during the period. KCG Holdings Inc. purchased a new stake in shares of Dynavax Technologies Corporation in the first quarter worth approximately $402,000. Finally, Lord Abbett & CO. LLC purchased a new stake in shares of Dynavax Technologies Corporation in the second quarter worth approximately $7,777,000. Institutional investors and hedge funds own 58.55% of the company’s stock.
TRADEMARK VIOLATION WARNING: This article was originally reported by Stock Observer and is the property of of Stock Observer. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.thestockobserver.com/2017/11/14/dynavax-technologies-corporation-dvax-trading-down-9-4.html.
Dynavax Technologies Corporation Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.